Innate Pharma S.A. (IPHYF)
USD 2.9
(0.0%)
USD 2.9
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 184.19 Million EUR | -11.39% |
| 2022 | 207.86 Million EUR | -22.29% |
| 2021 | 267.49 Million EUR | -12.99% |
| 2020 | 307.42 Million EUR | -23.4% |
| 2019 | 401.36 Million EUR | -11.05% |
| 2018 | 451.21 Million EUR | 76.93% |
| 2017 | 255.02 Million EUR | -9.43% |
| 2016 | 281.57 Million EUR | -7.97% |
| 2015 | 305.95 Million EUR | 237.36% |
| 2014 | 90.69 Million EUR | 62.29% |
| 2013 | 55.88 Million EUR | 15.71% |
| 2012 | 48.29 Million EUR | -19.65% |
| 2011 | 60.1 Million EUR | 25.2% |
| 2010 | 48.01 Million EUR | -25.24% |
| 2009 | 64.21 Million EUR | 5.52% |
| 2008 | 60.86 Million EUR | -3.63% |
| 2007 | 63.15 Million EUR | -8.81% |
| 2006 | 69.25 Million EUR | 179.63% |
| 2005 | 24.76 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 151.49 Million EUR | 0.0% |
| 2024 Q1 | 151.49 Million EUR | -17.75% |
| 2023 Q1 | 199.04 Million EUR | -4.24% |
| 2023 Q2 | 199.04 Million EUR | 0.0% |
| 2023 Q4 | 184.19 Million EUR | 0.0% |
| 2023 Q3 | 184.19 Million EUR | -7.46% |
| 2023 FY | 184.19 Million EUR | -11.39% |
| 2022 Q2 | 280.43 Million EUR | 0.0% |
| 2022 Q1 | 280.43 Million EUR | 4.84% |
| 2022 FY | 207.86 Million EUR | -22.29% |
| 2022 Q3 | 207.86 Million EUR | -25.88% |
| 2022 Q4 | 207.86 Million EUR | 0.0% |
| 2021 Q3 | 267.49 Million EUR | 0.48% |
| 2021 FY | 267.49 Million EUR | -12.99% |
| 2021 Q4 | 267.49 Million EUR | 0.0% |
| 2021 Q2 | 266.21 Million EUR | 0.0% |
| 2021 Q1 | 266.21 Million EUR | -13.4% |
| 2020 Q2 | 333.06 Million EUR | 0.0% |
| 2020 Q4 | 307.42 Million EUR | 0.0% |
| 2020 FY | 307.42 Million EUR | -23.4% |
| 2020 Q1 | 333.06 Million EUR | -17.02% |
| 2020 Q3 | 307.42 Million EUR | -7.7% |
| 2019 Q4 | 401.36 Million EUR | 0.0% |
| 2019 FY | 401.36 Million EUR | -11.05% |
| 2019 Q1 | 352.55 Million EUR | -21.87% |
| 2019 Q2 | 352.55 Million EUR | 0.0% |
| 2019 Q3 | 401.36 Million EUR | 13.84% |
| 2018 FY | 451.21 Million EUR | 76.93% |
| 2018 Q4 | 451.21 Million EUR | 0.0% |
| 2018 Q3 | 451.21 Million EUR | 99.73% |
| 2018 Q2 | 225.91 Million EUR | 0.0% |
| 2018 Q1 | 225.91 Million EUR | -11.41% |
| 2017 FY | 255.02 Million EUR | -9.43% |
| 2017 Q4 | 255.02 Million EUR | 0.0% |
| 2017 Q3 | 255.02 Million EUR | 3.51% |
| 2017 Q2 | 246.38 Million EUR | 0.0% |
| 2017 Q1 | 246.38 Million EUR | -12.5% |
| 2016 Q3 | 281.57 Million EUR | -0.28% |
| 2016 FY | 281.57 Million EUR | -7.97% |
| 2016 Q4 | 281.57 Million EUR | 0.0% |
| 2016 Q2 | 282.35 Million EUR | 0.0% |
| 2016 Q1 | 282.35 Million EUR | -7.71% |
| 2015 Q1 | 305.08 Million EUR | 236.4% |
| 2015 Q2 | 305.08 Million EUR | 0.0% |
| 2015 Q3 | 305.95 Million EUR | 0.29% |
| 2015 Q4 | 305.95 Million EUR | 0.0% |
| 2015 FY | 305.95 Million EUR | 237.36% |
| 2014 Q2 | 103.46 Million EUR | 0.0% |
| 2014 Q3 | 90.69 Million EUR | -12.35% |
| 2014 Q4 | 90.69 Million EUR | 0.0% |
| 2014 FY | 90.69 Million EUR | 62.29% |
| 2014 Q1 | 103.46 Million EUR | 85.15% |
| 2013 Q2 | 41.82 Million EUR | 0.0% |
| 2013 FY | 55.88 Million EUR | 15.71% |
| 2013 Q4 | 55.88 Million EUR | 0.0% |
| 2013 Q3 | 55.88 Million EUR | 33.63% |
| 2013 Q1 | 41.82 Million EUR | -13.41% |
| 2012 Q4 | 48.29 Million EUR | 0.0% |
| 2012 Q2 | 55.81 Million EUR | 0.0% |
| 2012 FY | 48.29 Million EUR | -19.65% |
| 2012 Q3 | 48.29 Million EUR | -13.48% |
| 2011 Q4 | 60.1 Million EUR | 0.0% |
| 2011 Q2 | 41.47 Million EUR | 0.0% |
| 2011 FY | 60.1 Million EUR | 25.2% |
| 2010 Q2 | 55.29 Million EUR | 0.0% |
| 2010 FY | 48.01 Million EUR | -25.24% |
| 2010 Q4 | 48.01 Million EUR | 0.0% |
| 2009 FY | 64.21 Million EUR | 5.52% |
| 2009 Q4 | 64.21 Million EUR | 0.0% |
| 2008 FY | 60.86 Million EUR | -3.63% |
| 2007 FY | 63.15 Million EUR | -8.81% |
| 2006 FY | 69.25 Million EUR | 179.63% |
| 2005 FY | 24.76 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -374.15% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -2451.234% |
| SQZ Biotechnologies Company | 107.18 Million USD | -71.843% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -1645.244% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -41.458% |
| Mesoblast Limited | 667.9 Million USD | 72.422% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -254433.269% |
| Genus plc | 1.02 Billion USD | 82.098% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -13460.025% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -36809.54% |
| Marizyme, Inc. | 22.01 Million USD | -736.668% |
| ContraFect Corporation | 20.67 Million USD | -790.725% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -29276.874% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -47084.693% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -48095.731% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -12762.352% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -4342.644% |
| MultiCell Technologies, Inc. | 126.22 USD | -145930022.009% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -19501.485% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -43.33% |
| EV Biologics, Inc. | 431.71 Thousand USD | -42565.515% |
| Q BioMed Inc. | 3.51 Million USD | -5139.429% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -423.588% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -23801.179% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -70397.212% |
| Biomind Labs Inc. | 73.81 Thousand USD | -249419.771% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 60.205% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -513.671% |
| Skye Bioscience, Inc. | 11.94 Million USD | -1442.602% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -5459.684% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -6606.866% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -9306.293% |
| IMV Inc. | 31.33 Million USD | -487.841% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -26692.255% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -6975.649% |
| GB Sciences, Inc. | 103.44 Thousand USD | -177964.036% |
| Alpha Cognition Inc. | 2.45 Million USD | -7411.429% |
| HST Global, Inc. | 1526.00 USD | -12070214.548% |
| CSL Limited | 38.02 Billion USD | 99.516% |
| Halberd Corporation | 10.13 Thousand USD | -1818012.723% |
| Enzolytics Inc. | 361.7 Million USD | 49.077% |
| Resverlogix Corp. | 8.11 Million USD | -2169.784% |
| Affymax, Inc. | 7.44 Million USD | -2374.714% |
| SYBLEU INC | 330.46 Thousand USD | -55637.015% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -9708.561% |
| argenx SE | 4.54 Billion USD | 95.945% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -559.15% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -286.133% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -808437.817% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -1958.217% |
| AVAX Technologies, Inc. | 7.37 Million USD | -2396.802% |
| Zenith Capital Corp. | 7410.00 USD | -2485635.493% |
| Genscript Biotech Corporation | 3.38 Billion USD | 94.561% |
| Ember Therapeutics, Inc. | 184.00 USD | -100104791.304% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -57137.28% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -70373.745% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 58.73% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -12613.11% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 3.02 Million USD | -5988.852% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -249.506% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -19749.218% |
| BioStem Technologies, Inc. | 14.56 Million USD | -1165.037% |
| ONE Bio Corp. | 70.08 Million USD | -162.812% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -322513.585% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -7973622.944% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -18543.639% |
| Agentix Corp. | 261.39 Thousand USD | -70366.196% |
| LadRx Corporation | 2.3 Million USD | -7881.041% |
| Cell Source, Inc. | 195.17 Thousand USD | -94275.189% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -38229.064% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -51988.276% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -51988.276% |
| NovAccess Global Inc. | 62.24 Thousand USD | -295801.876% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -28695.634% |
| Itoco Inc. | 1.4 Million USD | -13055.966% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -192455.694% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -173666.981% |
| Kadimastem Ltd | 2.3 Million USD | -7894.21% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -241135.561% |
| CytoDyn Inc. | 11.13 Million USD | -1554.032% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -128731.519% |
| Mobile Lads Corp. | 52.00 USD | -354217207.692% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -1030062.192% |
| Qrons Inc. | 420.00 USD | -43855376.19% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -47683.88% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -33261.045% |
| Rebus Holdings, Inc. | 5000.00 USD | -3683760.0% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -44888.545% |
| International Stem Cell Corporation | 5.39 Million USD | -3317.31% |
| Bioxytran, Inc. | 137.63 Thousand USD | -133724.235% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -1127.804% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -1011.002% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -233055.696% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -21201.943% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -2350.353% |
| Neutra Corp. | 2851.00 USD | -6460545.388% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -468.392% |
| PureTech Health plc | 693.97 Million USD | 73.458% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -2182.133% |
| IXICO plc | 15.84 Million USD | -1062.548% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -2124.016% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -78.267% |
| CSL Limited | 38.02 Billion USD | 99.516% |
| Cellectis S.A. | 333.99 Million USD | 44.852% |